Fractyl Health, Inc. (NASDAQ:GUTS) Receives $7.40 Average PT from Analysts

Fractyl Health, Inc. (NASDAQ:GUTS) has been given an average recommendation of “Moderate Buy” by the five ratings firms that are covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating and four have issued a buy rating on the company. The average 12-month price objective among analysts that have covered the stock in the last year is $7.40.

GUTS has been the subject of a number of research analyst reports. Weiss Ratings reissued a “sell (e+)” rating on shares of Fractyl Health in a research report on Wednesday, October 8th. HC Wainwright reissued a “buy” rating and set a $8.00 price objective on shares of Fractyl Health in a research report on Tuesday, December 2nd. LADENBURG THALM/SH SH assumed coverage on Fractyl Health in a report on Thursday, August 28th. They issued a “buy” rating and a $3.60 target price on the stock. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and issued a $8.00 price target on shares of Fractyl Health in a research report on Friday.

Fractyl Health Stock Down 2.7%

Shares of Fractyl Health stock opened at $2.20 on Wednesday. Fractyl Health has a 12-month low of $0.82 and a 12-month high of $3.03. The company has a quick ratio of 4.27, a current ratio of 4.27 and a debt-to-equity ratio of 4.61. The stock has a 50 day moving average price of $1.54 and a two-hundred day moving average price of $1.48. The stock has a market capitalization of $301.49 million, a P/E ratio of -0.96 and a beta of 1.96.

Fractyl Health (NASDAQ:GUTS) last released its quarterly earnings results on Wednesday, November 12th. The company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.01). Equities analysts expect that Fractyl Health will post -1.61 earnings per share for the current year.

Hedge Funds Weigh In On Fractyl Health

Several large investors have recently bought and sold shares of GUTS. Nantahala Capital Management LLC acquired a new stake in Fractyl Health in the 3rd quarter worth $19,298,000. Alyeska Investment Group L.P. acquired a new stake in Fractyl Health during the third quarter worth about $8,981,000. Rosalind Advisors Inc. bought a new position in Fractyl Health during the third quarter valued at about $7,950,000. Woodline Partners LP raised its holdings in Fractyl Health by 821.1% in the 3rd quarter. Woodline Partners LP now owns 5,506,534 shares of the company’s stock valued at $8,755,000 after acquiring an additional 4,908,693 shares in the last quarter. Finally, General Catalyst Group Management LLC acquired a new position in Fractyl Health in the 2nd quarter valued at approximately $7,912,000.

About Fractyl Health

Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.

The company’s lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.